Table 1 Baseline values and outcomes for transferred and non-transferred patients
Transferred n = 68 | Non-transferred n = 65 | P value | |
|---|---|---|---|
Age, median (IQR), year | 62 (55–70) | 64 (54–71) | 0.77 |
Male sex, no. (%) | 47 (69) | 48 (74) | 0.54 |
BMI, median (IQR), kg/m2 | 29 (25–32) | 29 (27–33) | 0.27 |
SAPS II score at admissiona, median (IQR) | 33 (25–46) | 35 (27–42) | 0.53 |
SOFA score at admissiona, median (IQR) | 4 (3–6) | 3 (2–5) | 0.25 |
Onset of symptoms before ICU admission, median (IQR), days | 9 (7–12) | 10 (8–12) | 0.34 |
Alcohol chronic intoxication, no. (%) | 3 (3) | 7 (11) | 0.09 |
Cardiovascular comorbidities, no. (%) | 36 (53) | 34 (52) | 0.94 |
Respiratory comorbidities, no. (%) | 13 (19) | 15 (23) | 0.56 |
Renal comorbidities, no. (%) | 5 (7) | 7 (11) | 0.56 |
Metabolic comorbidities, no. (%) | 27 (38) | 24 (37) | 0.74 |
Malignant comorbidities, no. (%) | 4 (6) | 7 (11) | 0.36 |
Chronic betablockers medication, no. (%) | 15 (22) | 9 (14) | 0.22 |
Chronic ACE inhibitors medication, no. (%) | 23 (35) | 23 (34) | 0.85 |
Chronic corticosteroids medication, no. (%) | 3 (4) | 3 (5) | 0.99 |
Patients’ outcome and support at admission and over stay in Poitiers, Rennes, and Tours ICUs | |||
Proning, no. (%) | 24 (35) | 42 (65) | 0.001 |
Number of proning session(s), median (IQR) | 2.5 (1.5–4) | 3 (1–5) | 0.43 |
Implantation of veno-venous ECMO, no. (%) | 5 (7) | 7 (11) | 0.49 |
Length of veno-venous ECLS, median (IQR), days | 18 (6–38) | 9 (7–12) | 0.52 |
Vasopressors use, no. (%) | 44 (65) | 45 (69) | 0.58 |
Occurrence of AKI, no. (%) | 18 (26) | 29 (45) | 0.03 |
Need for RRT, no. (%) | 8 (12) | 9 (14) | 0.79 |
Occurrence of bacteremia, no. (%) | 10 (15) | 5 (8) | 0.31 |
Occurrence of thrombotic event, no. (%) | 25 (37) | 20 (31) | 0.54 |
Primary and secondary outcomes | |||
ICU mortality, no. (%) | 7 (10) | 8 (12) | 0.71 |
Hospital mortality, no. (%) | 8 (12) | 8 (12) | 0.92 |
ICU-acquired infections, no. (%) | 37 (54) | 34 (52) | 0.82 |
Length of mechanical ventilation, median (IQR), days | 18 (11–24) | 14 (8–20) | 0.007 |
Length of intra-venous sedation, median (IQR), days | 10 (6–17) | 11 (6–18) | 0.57 |
Duration of neuromuscular blocking agents, median (IQR), days | 2 (1–5) | 5 (3–9) | 0.008 |
Length of vasopressor use, median (IQR), days | 2.5 (2–5) | 3 (2–5) | 0.77 |
ICU length of stay, median (IQR), days | 22 (16–32) | 19 (11–28) | 0.07 |
Hospital length of stay, median (IQR), days | 36 (24–48) | 30 (19–45) | 0.11 |